Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
BERKELEY, Calif. , March 20, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced it will present safety and biomarker data for
View HTML
Toggle Summary Dynavax Exercises Option for $75 Million in Non-Dilutive Debt
Proceeds to fund HEPLISAV-B® commercialization activities and completion of ongoing immuno-oncology studies BERKELEY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has exercised its option to draw down $75 million of non-dilutive
View HTML
Toggle Summary Dynavax to Present at 39th Annual Cowen Healthcare Conference
BERKELEY, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Eddie Gray , Chief Executive Officer, will
View HTML
Toggle Summary Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
Fourth quarter 2018 HEPLISAV-B ® net product revenue of $3.9 million Phase Ib/2 safety data for inhaled DV281 will be presented at the AACR Annual Meeting SD-101 demonstrates consistent and meaningful clinical benefit to anti-PD-1 therapy Conference call to be held today at 4:30 p.m. ET / 1:30 p.m.
View HTML
Toggle Summary Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26
BERKELEY, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, will report its fourth quarter and full year 2018 financial
View HTML
Toggle Summary Heather Rowe Named Dynavax’s Vice President of Investor Relations and Corporate Communications
BERKELEY, Calif. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Heather Rowe has been appointed vice
View HTML
Toggle Summary Sam’s Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Available to Sam’s Club Patients
BERKELEY, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a leader in developing immunotherapies based on toll-like receptor (TLR) biology, and Sam’s Club, a leading membership warehouse club offering superior products, savings and services to millions of
View HTML
Toggle Summary Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Eddie Gray , Chief Executive Officer, will
View HTML
Toggle Summary Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
Conference Call to be held Today at 4:30pm ET / 1:30pm PT BERKELEY, Calif. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2018 along with an update on the launch progress of HEPLISAV-B
View HTML
Toggle Summary Dynavax to Host Third Quarter 2018 Financial Results Conference Call
BERKELEY, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September 30, 2018 after market close on Monday, November 5, 2018 , and host a conference call that day to review
View HTML